SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp, volatile decline and lagging performance versus other crypto assets have traders debating whether the selloff is a buying opportunity or evidence of further downside. Bulls point to its capped supply and Compounds development plans, while bears cite weak price action and broader crypto-market uncertainty.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention ahead of its quarterly report, with traders citing analyst upgrades and expectations that Mounjaro and Zepbound demand could support strong results and higher guidance. Optimism about its obesity-drug pipeline and recent record highs is balanced by concerns that expectations are already priced in, alongside competition and questions about oral-drug uptake.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils presidential runoff is driving attention, with traders positioning around the possibility of a Bolsonaro victory that they view as more market-friendly and debating whether the rally already reflects that outcome. Call buying signals an upside tilt, while elevated put hedging and event volatility show substantial uncertainty.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

XLM is drawing attention amid a sustained slide and repeated failures to hold key price levels, with many traders complaining about relentless selling and others treating the weakness as an accumulation opportunity. The debate centers on whether Stellars institutional and real-world-asset adoption, including anticipated DTCC-related activity, can lift demand for the token or whether its tokenomics and low fees limit price benefits.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Discussion centers on the Batchelar settlement over Interactive Brokers past margin-account liquidations, with traders sharing eligibility and payment details and warning about scams. Some also point to rising margin-loan balances as a broader leverage risk.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing bullish attention around the anticipated CashVM/Layla upgrade, with traders speculating that programmable features and low fees could attract demand; skeptics question BCHs utility and whether its price momentum can hold.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, volatile XCN price spike is driving attention, with traders noting a large candle despite no clear news catalyst. The community is split between buying the dip and viewing the recurring pumps followed by selloffs as a pump-and-dump pattern; some also link moves to broader Bitcoin-led market swings.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

Healthcares relative strength and defensive-sector rotation amid weakness in tech are driving attention, with traders noting XLVs recent run to highs. Bulls see the trend as intact, while others warn the rally may be extended and vulnerable to a pullback.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

The community is focused on a DAO-approved rule directing product revenue received by Pyth toward PYTH accumulation, viewing the expanded buyback mechanism as potential token demand; traders also point to Pyths Nasdaq data-distribution role and RWA activity. Sentiment is mostly bullish, though some question whether revenue-funded purchases can offset token unlocks and selling pressure.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLEs rally to fresh highs is drawing attention as crude remains elevated amid traders concerns about Middle East conflict, Hormuz shipping risks, and energy-infrastructure disruptions. The community is broadly bullish on the sectors momentum, while some caution that the run looks extended and could be vulnerable to profit-taking or a shift in headlines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt

ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallStPR NewswireNEW YORK, Oct. 22, 2026 Regulatory...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming...

ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & Korsinsky ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & KorsinskyPR NewswireNEW YORK, Oct. 21, 2026 Important Notice Regarding Alleged Payer Access and Reimbursement...

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDXPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- The DJS Law...

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 19, 2026 NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds...

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 19, 2026 LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz...

ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStPR NewswireNEW YORK, Oct. 15, 2026Promise vs. Reality: Ardelyx pointed investors...

ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses

ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your LossesPR NewswireSAN...

ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline

ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action DeadlinePR NewswireNEW YORK, Oct. 14, 2026Alert: Claims focus on alleged...

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle  

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Xphozah is used to lower high phosphate levels in patients with chronic kidney disease who are on dialysis.</li><li>Being moved into the bundle typically reduces pricing power and can slow adoption by dialysis providers compared with separate reimbursement.</li><li>Jefferies noted that the appellate court decision effectively resolves the long-running legal challenge.</li></ul>Shares of Ardelyx (ARDX) fell 8% on Friday after a federal appellate court reaffirmed a lower court decision and dismissed the company’s appeal regarding its drug Xphozah not being eligible for separate reimbursement under Medicare.The stock clocked its worst day since late February on Friday.<h2 class="st-heading-2">Court Decision Ends Legal Challenge</h2>The ruling clears the way for Xphozah to be included in Medicare’s End-Stage Renal Disease (ESRD) bundled payment system. Under this system, dialysis centers receive a fixed payment that covers most services and medications for patients. As a result, Xphozah will no longer be reimbursed separately under Medicare Part D.The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle. As a result, the appeals court dismissed Ardelyx’s case and upheld the lower court’s ruling.Xphozah is used to lower high phosphate levels in patients with chronic kidney disease who are on dialysis. Being moved into the bundle typically reduces pricing power and can slow adoption by dialysis providers compared with separate reimbursement.<h2 class="st-heading-2">Jefferies View</h2>Jefferies noted that the appellate court decision this morning effectively resolves the long-running legal challenge. The firm had viewed the appeal as a “free call option” and said investors had not been heavily focused on it as a major catalyst.“The loss shouldn’t fundamentally change anything,” Jefferies wrote in a research note.However, the analyst flagged that second-quarter sales of Ardelyx’s other product, IBSRELA, are likely to come in below consensus estimates. With the Medicare appeal now behind the company, Jefferies said shares could face some near-term pressure. The firm maintained its ‘Buy’ rating and $15 price target on Ardelyx, representing a potential upside of about 170% from the last closing price.Ardelyx’s two main products are IBSRELA, which treats irritable bowel syndrome with constipation and has shown strong growth, and Xphozah. The company has continued to report revenue growth from both drugs despite the reimbursement uncertainty surrounding Xphozah.<h2 class="st-heading-2">How Did ARDX Retail Traders React?</h2>On Stocktwits, retail sentiment around ARDX stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“The court case always was a long (as in: loooooooong) shot. Today’s news shouldn’t change a thing,” a Stocktwits user said.<stembedurl>https://www.stocktwits.com/Burning_Cash/message/657650626</stembedurl>“Fingers crossed that Ardelyx focuses on execution from now on,” another user wrote.<stembedurl>https://www.stocktwits.com/opportoni/message/657611320</stembedurl><a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> has fallen 5% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uncy-stock-on-track-for-worst-day-in-about-a-year-ahead-of-fda-decision-on-lead-drug/cZ1cy7NR7Wd">UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.08
Prev Close	$3.20
Open	$3.17
Dividend Yield	0.00%
50-Day Moving Average	$3.52
Beta	0.98
Avg. Volume	4.16M
PE Ratio	-13.62

52-Week High	$8.40
52-Week Low	$3.02
Market Capitalization	$767.5M
EPS (Annual)	-$0.2556
Price to Book	5.15
Revenue Per Employee	$832,965.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARDX Fundamentals